MedMen Enterprises Inc. MMNFF revealed Tuesday that it has secured $100 million in financing via a private sale of its units in a deal led by Serruya Private Equity.
At the same time, the company disclosed that Tilray, Inc. TLRY acquired the majority of MedMen’s outstanding senior secured convertible notes that were originally held by certain funds affiliated with Gotham Green Partners LLC (GGP) and others.
The Analyst
Cantor Fitzgerald analyst Pablo Zuanic upgraded his rating on MedMen’s stock from Underweight to Neutral and established a price target of $0.30.
The Thesis
Tilray is investing around $118 million in MedMen in order to acquire some 21% contingent stake, based on which it seems that 100% MedMen equity has a value of $561 million, compared to its current market cap of $220 million, explained the analyst.
Zuanic further noted that this deal will not likely double MedMen's valuation because, as seen with other companies such as Acreage Holdings ACRDF, “stocks with equity investments/valuations contingent on the federal permissibility of cannabis tend to trade at steep discounts to their contingent offer prices.”
Nevertheless, with momentum changing for the company because of recent milestones, Cantor decided to rate the stock Neutral.
“On fully diluted pro-forma numbers, we calculate MedMen trades at 3.4x FactSet consensus CY22E sales compared with 3.1x for the US MSO average,” Zuanic said.
In conclusion, the analyst stressed that MedMen's premium should “stick” thanks to the new deal with Tilray.
The Price Action
MedMen’s shares were trading 1.49% higher at $0.267 per share at the time of writing Wednesday morning.
Photo: Courtesy of davide ragusa on Unsplash
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!